Given that MAP-kinases are associated with the development of systemic inflammation [14], our finding raises the question of whether enhanced p38 activation provides a target for immune suppression in AP patients or if it represents a vital counter-reaction of cells to inhibit NFκB, and should therefore be strengthened rather than depressed. The gene discussed is NFKB1; the disease is alkaline phosphatase measurement.